Protecting the gains: analysis of HIV treatment and service delivery programme data and interventions implemented in 19 African countries during COVID-19.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
11 2022
Historique:
received: 16 03 2022
accepted: 20 10 2022
entrez: 24 11 2022
pubmed: 25 11 2022
medline: 26 11 2022
Statut: ppublish

Résumé

The potential disruption in antiretroviral therapy (ART) services in Africa at the start of the COVID-19 pandemic raised concern for increased morbidity and mortality among people living with HIV (PLHIV). We describe HIV treatment trends before and during the pandemic and interventions implemented to mitigate COVID-19 impact among countries supported by the US Centers for Disease Control and Prevention (CDC) through the President's Emergency Plan for AIDS Relief (PEPFAR). We analysed quantitative and qualitative data reported by 10,387 PEPFAR-CDC-supported ART sites in 19 African countries between October 2019 and March 2021. Trends in PLHIV on ART, new ART initiations and treatment interruptions were assessed. Viral load coverage (testing of eligible PLHIV) and viral suppression were calculated at select time points. Qualitative data were analysed to summarize facility- and community-based interventions implemented to mitigate COVID-19. The total number of PLHIV on ART increased quarterly from October 2019 (n = 7,540,592) to March 2021 (n = 8,513,572). The adult population (≥15 years) on ART increased by 14.0% (7,005,959-7,983,793), while the paediatric population (<15 years) on ART declined by 2.6% (333,178-324,441). However, the number of new ART initiations dropped between March 2020 and June 2020 by 23.4% for adults and 26.1% for children, with more rapid recovery in adults than children from September 2020 onwards. Viral load coverage increased slightly from April 2020 to March 2021 (75-78%) and viral load suppression increased from October 2019 to March 2021 (91-94%) among adults and children combined. The most reported interventions included multi-month dispensing (MMD) of ART, community service delivery expansion, and technology and virtual platforms use for client engagement and site-level monitoring. MMD of ≥3 months increased from 52% in October 2019 to 78% of PLHIV ≥ age 15 on ART in March 2021. With an overall increase in the number of people on ART, HIV programmes proved to be resilient, mitigating the impact of COVID-19. However, the decline in the number of children on ART warrants urgent investigation and interventions to prevent further losses experienced during the COVID-19 pandemic and future public health emergencies.

Identifiants

pubmed: 36419346
doi: 10.1002/jia2.26033
pmc: PMC9684677
doi:

Substances chimiques

Anti-Retroviral Agents 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e26033

Subventions

Organisme : PEPFAR
Pays : United States

Informations de copyright

© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

HIV Res Clin Pract. 2021 Aug;22(4):102-118
pubmed: 34514963
N Engl J Med. 2020 Jul 16;383(3):e11
pubmed: 32302075
Curr HIV/AIDS Rep. 2019 Aug;16(4):324-334
pubmed: 31230342
Pan Afr Med J. 2020 Nov 19;37:255
pubmed: 33598070
PLoS One. 2018 Dec 14;13(12):e0208814
pubmed: 30550574
J Int AIDS Soc. 2020 Apr;23(4):e25482
pubmed: 32239657
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853
J Int AIDS Soc. 2020 Sep;23(9):e25622
pubmed: 32996705
J Med Virol. 2021 Mar;93(3):1687-1693
pubmed: 32949148
Clin Infect Dis. 2022 Jan 29;74(2):171-179
pubmed: 33993219
J Int AIDS Soc. 2020 Aug;23(8):e25587
pubmed: 32767707
J Int AIDS Soc. 2020 May;23(5):e25503
pubmed: 32378345
J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):280-291
pubmed: 32665460
Arch Public Health. 2021 Jan 4;79(1):1
pubmed: 33390163
J Int AIDS Soc. 2021 Oct;24 Suppl 6:e25794
pubmed: 34713578
Trop Med Health. 2020 Apr 10;48:18
pubmed: 32288543
J Int AIDS Soc. 2018 Nov;21(11):e25207
pubmed: 30450699
J Int AIDS Soc. 2021 Jun;24(6):e25704
pubmed: 34105884
PLoS One. 2016 Dec 1;11(12):e0166444
pubmed: 27907084
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
Lancet Glob Health. 2021 May;9(5):e628-e638
pubmed: 33865471
Curr HIV/AIDS Rep. 2019 Dec;16(6):467-474
pubmed: 31776974
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21650
pubmed: 28770594
J Virus Erad. 2018 Nov 15;4(Suppl 2):40-46
pubmed: 30515313
J Int AIDS Soc. 2020 Nov;23(11):e25640
pubmed: 33247517
Lancet HIV. 2020 Sep;7(9):e629-e640
pubmed: 32771089

Auteurs

Pamela J Bachanas (PJ)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Helen M Chun (HM)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Neha Mehta (N)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

John Aberle-Grasse (J)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

KaeAnne Parris (K)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Michelle Williams Sherlock (MW)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Spencer Lloyd (S)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Clement Zeh (C)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Daphne K Makwepa (DK)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Gaborone, Botswana.

Max L Kapanda (ML)

National ART Program, Ministry of Health and Wellness, Gaborone, Botswana.

Emily Kainne Dokubo (EK)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Yaounde, Cameroon.

Leonard Bonono (L)

National AIDS Control Committee, Ministry of Public Health, Yaounde, Cameroon.

Shirish Balachandra (S)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Abidjan, Cote d' Ivoire.

Eboi Ehui (E)

National AIDS Control Program, Ministry of Health and Public Hygiene, Abidjan, Cote d' Ivoire.

Peter Fonjungo (P)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of the Congo.

Aimé M Nkoso (AM)

Ministry of Health, Kinshasa, Democratic Republic of Congo.

Sikhathele Mazibuko (S)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Mbabane, Eswatini.

Velephi N Okello (VN)

Health Services - Clinical, Ministry of Health, Mbabane, Eswatini.

Fana Tefera (F)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Addis Ababa, Ethiopia.

Mirtie Getachew (M)

Disease Prevention and Control Directorate, Ministry of Health, Addis Ababa, Ethiopia.

Elizabeth M Katiku (EM)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Nairobi, Kenya.

Andrew Mulwa (A)

Preventive and Promotive Health, Ministry of Health, Nairobi, Kenya.

Fred M Asiimwe (FM)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Maseru, Lesotho.

Tapiwa F Tarumbiswa (TF)

Ministry of Health, Maseru, Lesotho.

Andrew F Auld (AF)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Lilongwe, Malawi.

Rose Nyirenda (R)

Ministry of Health, Lilongwe, Malawi.

Alzira P Dos Santos De Louvado (AP)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Maputo, Mozambique.

Irenio Gaspar (I)

HIV Program, Ministry of Health, Maputo, Mozambique.

Steven Y Hong (SY)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Windhoek, Namibia.

Laimi Ashipala (L)

HIV/STI Sub-Division, Directorate Special Programmes, Ministry of Health and Social Services, Windhoek, Namibia.

Christopher Obanubi (C)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Abuja, Nigeria.

Akudo Ikpeazu (A)

National AIDS/STI Control Programme, Federal Ministry of Health, Abuja, Nigeria.

Canisious Musoni (C)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Kigali, Rwanda.

Emmanuel Yoboka (E)

Ministry of Health, Kigali, Rwanda.

Simangele Mthethwa (S)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Pretoria, South Africa.

Zukiswa Pinini (Z)

HIV, AIDS & STIs Cluster, National Department of Health, Pretoria, South Africa.

Sudhir Bunga (S)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Juba, South Sudan.

John Rumunu (J)

Preventive Health Services, Ministry of Health, Juba, Republic South Sudan.

Daniel J Magesa (DJ)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Dar es Salaam, Tanzania.

Beatrice Mutayoba (B)

Ministry of Health, Dar es Salaam, Tanzania.

Lisa J Nelson (LJ)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Kampala, Uganda.

Cordelia Katureebe (C)

Ministry of Health, Kampala, Uganda.

Simon Agolory (S)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Lusaka, Zambia.

Lloyd B Mulenga (LB)

Ministry of Health, Lusaka, Zambia.

Ponesai Nyika (P)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Harare, Zimbabwe.

Owen Mugurungi (O)

Ministry of Health, Harare, Zimbabwe.

Tedd Ellerbrock (T)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Kiren Mitruka (K)

Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH